EmpA protein, Vibrio anguillarum

Heart failure (HF) is one of the most pervasive complications occurring in patients with type 2 diabetes (T2D). The risk of HF… (More)

In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)

In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)

In der placebokontrollierten EMPA-REGOUTCOME-Studie mit ca. 7000 Patienten mit Diabetes und kardiovaskulären Erkrankungen… (More)

INTRODUCTION The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the… (More)

The EMPA-REG OUTCOME study reported that a sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin suppresses… (More)

In the EMPA-REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure (SBP and DBP) compared with… (More)

The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure… (More)

The EMPA-REG OUTCOME study, in which the sodium-glucose cotransporter 2 (SGLT2) inhibitor empaglifl ozin showed impressive benefi… (More)

EMPA-REG OUTCOME is an international, prospective, placebo-controlled clinical trial investigating the cardiovascular outcomes of… (More)